Answers are grounded in this paper and cite their sources.
This study assesses newly synthesized chromones with a 3,4‐dihydropyrimidin‐2(1H)‐one core at C‐3, combined with triazole derivatives for their antidiabetic potential. Compounds 5a and 5b showed strong inhibition of α‐glucosidase, with IC 50 values of 58.99 ± 4.15 nmol and 49.18 ± 2.18 nmol. Docking studies indicated effective binding within the active site of α‐glucosidase (−10.7 kcal/mol for 5a and −10.9 kcal/mol for 5b). Computational assessments suggested both compounds have favorable profiles for drug‐likeness, ADME, and toxicity, highlighting their potential as therapeutic agents for diabetes.
No takes yet. Share an insight, caveat, or question.
Taviti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: